About
About Yuhan Corporation
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Visit company website
5 years, 5 months ago
Yuhan Corporation is currently in a long term downtrend where the price is trading 0.1% below its 200 day moving average.
From a valuation standpoint, the stock is 70.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Yuhan Corporation's total revenue rose by 17.2% to $461B since the same quarter in the previous year.
Its net income has increased by 173.0% to $13B since the same quarter in the previous year.
Finally, its free cash flow fell by 161.7% to $-3B since the same quarter in the previous year.
Based on the above factors, Yuhan Corporation gets an overall score of 3/5.